Mn Services Vermogensbeheer B.V. increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 69,147 shares of the medical research company’s stock after buying an additional 800 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Thermo Fisher Scientific were worth $18,927,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund boosted its holdings in shares of Thermo Fisher Scientific by 44,296.5% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 19,565,960 shares of the medical research company’s stock valued at $87,000 after acquiring an additional 19,521,889 shares during the period. Norges Bank acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $946,280,000. FMR LLC lifted its holdings in shares of Thermo Fisher Scientific by 33.4% during the fourth quarter. FMR LLC now owns 8,671,713 shares of the medical research company’s stock worth $1,940,642,000 after purchasing an additional 2,172,574 shares during the period. BlackRock Inc. lifted its holdings in shares of Thermo Fisher Scientific by 3.7% during the fourth quarter. BlackRock Inc. now owns 26,177,278 shares of the medical research company’s stock worth $5,858,214,000 after purchasing an additional 944,035 shares during the period. Finally, Cantillon Capital Management LLC increased its position in shares of Thermo Fisher Scientific by 91.3% in the fourth quarter. Cantillon Capital Management LLC now owns 1,024,930 shares of the medical research company’s stock valued at $229,369,000 after buying an additional 489,081 shares in the last quarter. Hedge funds and other institutional investors own 87.96% of the company’s stock.
NYSE:TMO traded down $0.98 during trading hours on Friday, hitting $285.26. 1,381,012 shares of the company’s stock traded hands, compared to its average volume of 1,633,012. The firm has a market capitalization of $114.08 billion, a price-to-earnings ratio of 25.65, a PEG ratio of 1.87 and a beta of 1.08. Thermo Fisher Scientific Inc. has a twelve month low of $202.83 and a twelve month high of $288.07. The company has a current ratio of 1.69, a quick ratio of 1.16 and a debt-to-equity ratio of 0.61.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 16th. Investors of record on Friday, June 14th will be paid a dividend of $0.19 per share. The ex-dividend date is Thursday, June 13th. This represents a $0.76 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s payout ratio is 6.83%.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Tuesday, May 14th. Wolfe Research assumed coverage on Thermo Fisher Scientific in a report on Thursday, May 30th. They issued an “outperform” rating for the company. Barclays boosted their price target on Thermo Fisher Scientific from $295.00 to $300.00 and gave the company an “overweight” rating in a report on Monday, March 18th. Deutsche Bank upped their price objective on Thermo Fisher Scientific from $275.00 to $300.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Finally, UBS Group upped their price objective on Thermo Fisher Scientific from $305.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, May 23rd. Two analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $295.92.
In related news, CEO Marc N. Casper sold 50,713 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $273.21, for a total transaction of $13,855,298.73. Following the completion of the sale, the chief executive officer now directly owns 302,193 shares of the company’s stock, valued at approximately $82,562,149.53. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $268.29, for a total value of $670,725.00. Following the sale, the chief financial officer now directly owns 40,029 shares of the company’s stock, valued at $10,739,380.41. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 53,488 shares of company stock valued at $14,600,474. 0.45% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This report was reported by Rockland Register and is the property of of Rockland Register. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://rocklandregister.com/2019/06/14/mn-services-vermogensbeheer-b-v-has-18-93-million-stake-in-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: Limitations of the P/E Growth ratio
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.